Short-term Outcomes of Anti-VEGF therapy in Neovascular Age-related Macular Degeneration with Initially Low Visual Acuity
https://doi.org/10.18008/1816-5095-2025-1-120-126
Abstract
Purpose: To study the short-term outcomes of anti-VEGF therapy in neovascular age-related macular degeneration (nAMD) in patients with initially low visual acuity.
Patients and methods. Treatment-naive nAMD patients with best-corrected visual acuity (BCVA) less than 0.1 were included. All participants received three monthly injections of brolucizumab. Outcome measures were evaluated at two months after the last injection. At the beginning and at the end of the follow-up, all patients received standard ophthalmic examination and optical coherence tomography (OCT) to assess anatomical changes in the macula.
Results. The study included 23 eyes (17 males and 6 females, 79.2 ± 7.1 years). During the study period, BCVA changed from 1.47 ± 0.36 to 1.36 ± 0.31 LogMAR (p = 0.77), central retinal thickness decreased from 393.1 ± 159.8 to 348.3 ± 199.2 µ m (p = 0.11). Macular volume decreased from 7.3 to 6.0 mm3 (p < 0.05). Severe morphological changes of the macula were found at baseline, including retinal pigment epithelium atrophy, subretinal fibrosis, giant intraretinal cysts and/or subretinal hemorrhages.
Conclusion. Patients with nAMD, low visual acuity, and severe anatomical changes in the macula have a very limited or no benefits from anti-VEGF therapy.
About the Authors
A. N. Kulikov
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
Kulikov Alexey N., MD, Professor, head of the ophthalmology department
Botkinskaya str., 21, St Petersburg, 194044
V. R. Zhalimova
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
Zhalimova Valeria R., ophthalmologist of the ophthalmology department
Botkinskaya str., 21, St Petersburg, 194044
D. S. Maltsev
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
Maltsev Dmitrii S., MD, head of medical retina division of ophthalmology department
Botkinskaya str., 21, St Petersburg, 194044
References
1. Keenan TDL, Cukras CA, Chew EY. Age-Related Macular Degeneration: Epidemiology and Clinical Aspects. Adv Exp Med Biol. 2021;1256:1–31. doi: 10.1007/978-3-030-66014-7_1.
2. Gilmanshin TR, Zainullin RM, Kudoyarova KI, Kalanov MR, Khalimov TA. Treatment of age-related macular degeneration: opportunities and prospects. Literature review. Point of view. East-West. 2019;(2):124–128 (In Russ.). doi: 10.25276/2410-1257-2019-2-124-128.
3. Durasov AB. Therapy of neovascular age-related macular degeneration: reasonable expectations of the doctor and the patient. Clinical ophthalmology. 2021;21(3):169–174 (In Russ.). doi: 10.32364/2311-7729-2021-21-3-169-174.
4. Bobykin EV, Krokhalev VYa, Beresneva NS, Buslaev RV, Morozova OV. Reasons for anti-VEGF treat-ment discontinuation in real clinical practice: results of a phone survey of patients with macular diseases. Ophthalmology Journal. 2020;13(4):73–82. doi: 10.17816/OV41716.
5. Kulikov AN, Zhalimova VR, Maltsev DS. Long-Term Outcomes of Nonadherence to Anti-VEGF Therapy in Advanced Neovascular Age-Related Macular Degeneration. Ophthalmology in Russia. 2022;19(3):658–664 (In Russ.). doi: 10.18008/1816-5095-2022-3-658-664.
6. Nguyen QD, Das A, Do DV, Dugel PU, Gomes A, Holz FG, Koh A, Pan CK, Sepah YJ, Patel N, MacLeod H, Maurer P. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020 Jul;127(7):963–976. doi: 10.1016/j.ophtha.2019.12.031.
7. Dugel PU, Koh A, Ogura Y. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84. doi: 10.1016/j.ophtha.2019.04.017.
8. Budzinskaya MV, Plyukhova AA, Afanasyeva MA, Gorkavenko FV. New criteria of effectiveness of anti-VEGF therapy in exudative age-related macular degeneration. Russian Annals of Ophthalmology. 2022;138(4):58–66 (In Russ.). doi: 10.17116/oftalma202213804158.
9. Tenbrock L, Wolf J, Boneva S, Schlecht A, Agostini H, Wieghofer P, Schlunck G, Lange C. Subretinal fibrosis in neovascular age-related macular degeneration: current concepts, therapeutic avenues, and future perspectives. Cell Tissue Res. 2022 Mar;387(3):361–375. doi: 10.1007/s00441-021-03514-8.
10. Pliukhova AA, Budzinskaia MV. The role of anti-VEGF therapy in geographic atrophy progression. Russian Annals of Ophthalmology. 2018;134(5):289–293 (In Russ.). doi: 10.17116/oftalma2018134051289.
11. Maltsev DS, Kulikov AN, Perminova SM, Burnasheva MA, Vasiliev AS. Мultimodal imaging in nonexudative choroidal neovascularization: A Pilot Study of Status of Retinal Pigment Epithelium. Retina. 2023 Nov 1;43(11):2019–2026. doi: 10.1097/IAE.0000000000003896.
12. Yalçın G, Özdek Ş, Baran Aksakal FN. Defining Cystoid Macular Degeneration in Diabetic Macular Edema: An OCT-Based Single-center Study. Turk J Ophthalmol. 2019 Dec 31;49(6):315–322. doi: 10.4274/tjo.galenos.2019.22687.
13. Boiko EV, Maltsev DS. Quantitative optical coherence tomography analysis of retinal degenerative changes in diabetic macular edema and neovascular agerelated macular degeneration. Retina. 2018 Jul;38(7):1324–1330. doi: 10.1097/IAE.0000000000001696.
14. Ying GS, Maguire MG, Daniel E, Grunwald JE, Ahmed O, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016 Feb;123(2):352–360. doi: 10.1016/j.ophtha.2015.09.046.
15. Kozina EV, Zabolotny AV, Malafeev AV. Analysis of clinical cases of anti-VEGF therapy of massive subretinal hemorrhages complicating age-related macular degeneration. Ophthalmosurgery. 2016;3:28–32 (In Russ.). doi: 10.25276/0235-4160-2016-3-28-31.
Review
For citations:
Kulikov A.N., Zhalimova V.R., Maltsev D.S. Short-term Outcomes of Anti-VEGF therapy in Neovascular Age-related Macular Degeneration with Initially Low Visual Acuity. Ophthalmology in Russia. 2025;22(1):120-126. (In Russ.) https://doi.org/10.18008/1816-5095-2025-1-120-126
Views:
146
Email this article 